Incyte (Nasdaq: INCY) and Genesis Therapeutics have entered into a strategic partnership to advance drug discovery using artificial intelligence. The collaboration will leverage Genesis’ proprietary AI platform, GEMS (Genesis Exploration of Molecular Space), to develop novel small molecule medicines for high-impact targets selected by Incyte. Under the agreement, Incyte will gain exclusive rights to any resulting clinical developments and commercialization opportunities.
Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte, stated that the company is committed to integrating transformative technologies into its drug discovery efforts. He explained that Genesis’ AI capabilities provide an opportunity to accelerate the development of breakthrough small molecules for complex diseases.
Evan Feinberg, Ph.D., Founder and CEO of Genesis, emphasized that AI is redefining the discovery of small molecule medicines and highlighted the significance of partnering with Incyte to combine its deep expertise in pharmaceutical innovation with AI-driven advancements. He added that the shared goal of the collaboration is to bring critical treatments to patients more efficiently.
Under the terms of the agreement, Genesis will receive an upfront payment of $30 million. The companies will initially collaborate on two targets, with Incyte retaining the option to nominate an additional target for a predetermined fee. If all development, regulatory, and commercial milestones are met, Genesis could receive up to $295 million per target, in addition to tiered royalties on future sales of approved collaboration products.
The partnership reflects Incyte’s ongoing efforts to integrate AI into pharmaceutical research and Genesis’ commitment to leveraging generative AI for drug discovery. The GEMS platform utilizes language models, diffusion models, and physical simulations to generate optimized molecules for complex biological targets.
